Cisatracurium Besylate
Generic Name: cisatracurium besylate
Brand Names:
Cisatracurium Besylate
Cisatracurium besylate is a nondepolarizing skeletal neuromuscular blocker with intermediate onset and duration, used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery and mechanical ventilation.
Overview
Cisatracurium besylate is a nondepolarizing skeletal neuromuscular blocker with intermediate onset and duration, used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery and mechanical ventilation.
Uses
Adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Provides skeletal muscle relaxation during surgery and mechanical ventilation in ICU settings.
Dosage
Initial bolus doses of 0.15 to 0.2 mg/kg for adults with specific guidance for pediatric, geriatric, and special populations. Continuous infusion rates range from 1 to 2 mcg/kg/minute for maintenance. Requires careful dosing based on patient population.
Side Effects
Most common adverse effects include bradycardia, hypotension, flushing, bronchospasm, and rash, occurring at rates below 0.4%.
Interactions
Certain medications potentiate effects, including inhalational anesthetics, antibiotics, and magnesium salts. Phenytoin and carbamazepine may reduce efficacy.
Warnings
Risks include residual paralysis, benzyl alcohol toxicity in infants, seizure potential from metabolites, hypersensitivity reactions, medication errors, and inadequate anesthesia complications. Contraindicated in hypersensitivity to cisatracurium. 10 mL multiple-dose vials contraindicated for pediatric patients under 1 month due to benzyl alcohol.
Pregnancy
Animal studies showed no evidence of fetal harm at 0.8 times human exposure. No clinical trial data available on cisatracurium use in pregnancy.
Frequently Asked Questions
What is Cisatracurium Besylate used for?▼
Adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients 1 month to 12 years of age. Provides skeletal muscle relaxation during surgery and mechanical ventilation in ICU settings.
What are the side effects of Cisatracurium Besylate?▼
Most common adverse effects include bradycardia, hypotension, flushing, bronchospasm, and rash, occurring at rates below 0.4%.
Can I take Cisatracurium Besylate during pregnancy?▼
Animal studies showed no evidence of fetal harm at 0.8 times human exposure. No clinical trial data available on cisatracurium use in pregnancy.
What are the important warnings for Cisatracurium Besylate?▼
Risks include residual paralysis, benzyl alcohol toxicity in infants, seizure potential from metabolites, hypersensitivity reactions, medication errors, and inadequate anesthesia complications. Contraindicated in hypersensitivity to cisatracurium. 10 mL multiple-dose vials contraindicated for pediatric patients under 1 month due to benzyl alcohol.
Related Medications
Anticavity Oral Rinse
anticavity oral rinse
PURPOSE Anticavity
Upadacitinib
upadacitinib
Janus Kinase Inhibitor [EPC]
11 DESCRIPTION RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3 S ,4 R )-3-Ethyl-4-(3 H -imidazo[1,2- a ]pyrrolo[2,3- e ]pyrazin-8-yl)- N -(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 o C.
Sterile Water
sterile water
This preparation is designed solely for parenteral use, only after addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injection. Sterile Water for Injection, USP is a sterile, nonpyrogenic preparation of water for injection, which contains no bacteriostat, antimicrobial agent or added buffer, and is supplied only in single-dose containers to dilute or dissolve drugs for injection.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.